Correction to: Oncogene https://doi.org/10.1038/s41388-022-02585-3, published online 7 January 2023
In this article the affiliation details for Author J. Gligorov were incorrectly given as 7,8,9,10,11,12,13,14, but should have been ‘7, 14’ and for Author J. Y. Pierga were incorrectly given as 1,2,3,4,5,6,7,8,9,10,11,12,13 but should have been 1, 13.
In the abstract, the word “data” in the second sentence was misspelled “datda”
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bello Roufai, D., Gonçalves, A., De La Motte Rouge, T. et al. Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene 42, 1417 (2023). https://doi.org/10.1038/s41388-023-02615-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-023-02615-8
